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Atypical teratoid rhabdoid tumors (AT/RTs) are rare pediatric brain tumors characterized
by bialleic loss of the SMARCB1 tumor suppressor gene. In contrast to pediatric AT/RT
that has a simple genome, very little is known about the adult AT/RT genomic landscape.
Using a combination of whole-exome sequencing and high-resolution SNP array in a
single adult pituitary AT/RT, we identified a total of 47 non-synonymous mutations, of
which 20 were predicted to cause non-conservative amino acid substitutions, in addition
to a subclone of cells with trisomy 8. We suggest that adult AT/RT may not be markedly
dissimilar to other adult brain tumors where mutations in a range of genes, reflecting the
functional specialization of different brain regions, but including SMARCB1 inactivation,
may be required for its pathogenesis.
Keywords: exome sequencing, atypical teratoid rhabdoid tumor, copy number variation, adult, SMARCB1,
trisomy 8
INTRODUCTION
Atypical teratoid rhabdoid tumors (AT/RTs) are rare and aggressive pediatric malignant rhabdoid
tumors (MRT) that occur within the brain. AT/RTs are characterized by biallelic loss of SMARCB1,
a tumor suppressor gene on chromosome 22q11.23, which encodes INI-1. INI-1 is a canonical non-
catalytic component of multimeric chromatin remodeling complexes (1, 2) that act as transrepres-
sors for proto-oncogenes, such as c-MYC (3). Investigations using a combination of whole-exome
sequencing (WES) and high-resolution (hr)-SNP arrays have demonstrated that the untreated
pediatric primary AT/RT genome is remarkably simple with very few detectable somatic mutations
or copy number variations (4).
Atypical teratoid rhabdoid tumor is an extremely rare malignancy in adults with only 42 cases
having been reported to date, of which 8 cases, all in female patients, have arisen from the pituitary
(5, 6). Here for the first time, we report the findings of WES on a primary pituitary AT/RT from a
48-year-old peri-menopausal female.
The patient had initially presented to the referring neurosurgical center with a 2-week his-
tory of visual field disturbance. An initial contrast CT brain scan demonstrated an enhancing
pituitary mass, and this was deemed to have malignant characteristics on a contrast MRI scan.
Transsphenoidal pituitary surgery was performed to achieve immediate debulking and tissue
material was sent for pathological analysis. This procedure was deemed to have been a gross tumor
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resection on post-operative MRI. The patient was discharged
without complication and had achieved an almost complete symp-
tomatic response in her presenting visual symptoms. Preliminary
histopathology review at the referring center diagnosed this tumor
as a “small round blue cell tumor,” but no surplus tissue material
was available for further investigations.
The patient was re-admitted 2weeks later after her initial
surgery with an abrupt recurrence of her original visual field
symptoms. A repeat MRI scan confirmed recurrence of the pitu-
itary mass. Given the rapid tempo of re-growth, the neurosurgical
team at the referring center performed a repeat gross tumor resec-
tion procedure where additional, multiple, tissue samples were
sent for histopathology. Given the atypical preliminary diagnosis
from the first tumor resection, tissue material from this second
surgery was sent to our reference pediatric brain tumor pathology
laboratory. Sufficient surplus tissue material was available on this
occasion for additional immunohistochemical and genetic inves-
tigations to be performed at our center. The patient represented to
the referring center 10 days after her second surgery with further
neurological symptoms that were confirmed onMRI to have been
caused by a second local post-surgical recurrence.
Second pathological review at our center found the presence
of rhabdoid cells in over 90% of the tumor material (Figure S1A
in Supplementary Material) and negative immunostaining for
INI-1 within the tumor except for intratumoral blood vessels
(Figure S1B in SupplementaryMaterial). Although genetic confir-
mation of SMARCB1 inactivation was still pending, the patholog-
ical diagnosis was compelling for AT/RT since the predominant
cellular morphology was rhabdoid in nature with negative INI-
1 immunostaining. Given these pathological findings, and the
clinically aggressive natural history of this tumor that was refrac-
tory to two serial gross tumor resection procedures performed
over a period of only 2weeks, the patient was transferred to our
oncology center, where she immediately commenced a multi-
agent, non-cross resistant, AT/RT chemotherapy regimen. This
chemotherapy regimen consisted of six planned cycles of vin-
cristine, doxorubicin, and cyclophosphamide (VDC) alternating
with ifosfamide, carboplatin, and etoposide (ICE) which was to
be followed by pituitary and cranio-spinal irradiation. The patient
refused intrathecal methotrexate treatment in-between systemic
chemotherapy cycles.
A mid-treatment MRI scan after administration of three cycles
of chemotherapy demonstrated a complete radiological response
in the sella turcica with no evidence of neuro-axis metastatic
disease. However, she was re-admitted 2weeks after this mid-
treatment MRI scan, and immediately prior to her fourth cycle of
chemotherapy, with progressively worsening neurological signs.
A repeat MRI brain scan diagnosed leptomeningeal disease, with-
out recurrence of the primary tumor, and she died 1week later
(Figures S2A,B in Supplementary Material). Her rapidly deteri-
orating neurological condition during this admission precluded
a diagnostic lumbar puncture being performed for cerebrospinal
fluid cytological/molecular pathological analysis.
METHODS
This study was carried out in accordance with the recommen-
dations of the Medical Research Ethical Committee (MREC)
in Newcastle-Upon-Tyne, UK. Tissue was stored in accordance
with local ethical approval for biobanking malignant tissue from
deceased patients (MREC: 10/H1306/50 – approval 2011).
Details about WES and SNP array methodology, data analysis
are provided in a Supplementary Appendix.
RESULTS
Whole-exome sequencing revealed a total of 98 somatic muta-
tions. The overall mutation rate was 1.89 per Mb of exome
sequence (Figure 1). Of the identified 98 mutations, 88 were
single nucleotide substitutions and 10 were indels. Of the 88
single nucleotide substitutions, 56 were transitions and 32 were
transversions. Of the 98 mutations detected, 49 were predicted
to alter the sequence of the encoded protein via missense,
nonsense, or frameshift mutations (Table S1 in Supplementary
Material).
Two of these 49 mutations were distinct biallelic mutations
in SMARCB1 at Exon 2 codon 49 (Ser49) C!G, which is pre-
dicted to cause a stop codon, and at Exon 5 codon 628+ 2
T!G, which is predicted to cause alternative splicing. Both
SMARCB1 mutations were present in the Cancer Gene Cen-
sus List1. A non-synonymous mutation in the mismatch repair
(MMR) gene MSH2 was also present (see Table S1 in Supple-
mentary Material). However, inactivating mutations inMSH2 are
known to cause microsatellite instability, which tends to result
in a substantially higher number of somatic mutations (>1000
per exome) than we have detected. Therefore, the identified
MSH2 mutation seems unlikely to have led to loss of MMR
activity.
Apart from the two separate SMARCB1 mutations, in sil-
ico bioinformatic analysis using POLYPHEN22 predicted that
20/47 of the remaining non-synonymous mutations could have
caused non-conservative amino acid substitutions that would
have been detrimental to protein function. Nineteen of these non-
synonymous mutations were novel in the COSMIC database. We
categorized these 20 mutated genes into four functionally distinct
groups based upon wild-type gene function (GeneDistiller 2):
Group 1: intracellular transport/cytoskeleton – tubulin and actin
dynamics genes; Group 2: stem cell differentiation genes; Group
3: cell metabolism genes; Group 4: cytotoxic resistance genes
(Table 1).
We used hrSNP array on the fresh-frozen tumor sample to
analyze the tumor for copy number variation and ploidy. We
identified a subclone of cells with isolated trisomy 8, which using a
C-MYC FISHprobe, was confirmed to be present in 11%ofAT/RT
cells (Figure S3 in Supplementary Material). We were unable to
investigate the mutational background of these +8 cells because
of a lack of surplus tissue.
DISCUSSION
The genetic analysis of this single adult AT/RT case, using a
combination of WES and hrSNP array, has demonstrated a
1http://cancer.sanger.ac.uk/cancergenome/projects/census/
2http://genetics.bwh.harvard.edu/pph2/
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FIGURE 1 | Summary of exome sequencing results comparing tumor and control skin tissue displayed as a Circos diagram. The outermost ring
indicates chromosomes. The next ring summarizes DNA copy number and shows a scatter plot of the log2 ratio of normalized DNA concentration (RPKM) in the
tumor and normal samples (red points). The green points indicate the inferred segmented copy number profile. The third ring from the outermost summarizes variant
allele frequencies across the chromosomes (red points) and segmented allele frequencies (green points). The innermost ring indicates the positions of somatic SNP
(circles) and indels (triangles). Somatic mutations likely to lead to a change in an encoded protein are colored green and those that are also included in the Cancer
Gene Census list are colored red. All other somatic mutations are colored gray.
greater level of genomic complexity than that has been pre-
viously recognized in children. We found a higher mutation
rate compared to the mean mutation rate of 0.19 per Mb of
exome sequence demonstrated in a series of 32 pediatric primary
AT/RTs examined by Lee et al. (4). Our own findings are also
distinct from those recently reported by Wu et al. in an adult
superior colliculus AT/RT that demonstrated only four muta-
tions on a background of SMARCB1 inactivation, which would
be comparable to the low background mutational frequency in
pediatric AT/RTs. These mutations were in MDM4, RHPN2,
FLT3, and NPRL3, but were not detected in our own patient’s
tumor (7).
Moreover, our finding of trisomy 8 in a minority of AT/RT
cells would be consistent with the concept of intratumoral het-
erogeneity that has already been demonstrated at the mutational
level in extracranial primary solid tumors (8, 9). In addition to
containing the locus for the c-MYC proto-oncogene, chromosome
8 also harbors loci for a number of other genes that have been
implicated in the development of tumor progression, such as
cancer cell migration (i.e., MT3-MMP), cell survival (i.e., BNIP3),
and dedifferentiation (i.e., Oct-4)3. However, in the absence of
cerebrospinal fluid cells for analysis from this patient at intra-
chemotherapy relapse, we were unable to confirm whether the
+8 subclone was causative in this patient’s leptomeningeal disease
progression.
In summary, we have identified a number of novel mutations
involving functionally unique genes, as well as copy number varia-
tion heterogeneity affecting chromosome 8 in an adult AT/RT, but
we are unable to establish the phenotypic effect of these changes
without performing functional studies. Similarly, we cannot prove
at this stage, without analysis of a larger set of adult AT/RTs, that
the mutations we have detected were specific to the pituitary site
of origin.
However, in combination, the adult AT/RT exome sequence
findings presented here, those of Wu et al. (7), and the pediatric
AT/RT transcriptomic data from Torchia et al. (10), would be
consistent with the hypothesis that the genomic landscape of
3http://atlasgeneticsoncology.org/Indexbychrom/idxa_8.html
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TABLE 1 | Twenty non-synonymous mutations predicted by POLYPHEN2 to
be detrimental to cognate protein function.
Functional groups Gene Novel to COSMIC database
(Yes (Y); No (N))
Group 1: tubulin/actin transport
genes
C16orf70 Y
C13orf25 Y
MEI1 Y
LRRCC1 Y
TTLL4 Y
JAKMIP1 Y
MCC Y
CTNNA3 Y
MYO5A Y
Group 2: stem cell differentiation
genes
PARD3B Y
TIAM2 Y
T Y
LNX1 Y
Group 3: metabolism genes PYGL N
MTO1 Y
POFUT1 Y
SLC25A1 Y
CYP1A1 Y
Group 4: cytotoxic resistance
genes
GSTA4 Y
APAF1 Y
a primary AT/RT is dependent upon the neuroanatomical site
in which it arises. This might be a reflection of the regionally
specified neural stem cell lineage from which the tumor arose.
We suggest that future studies in AT/RT should take an
extended integrative genomic approach by using next-generation
sequencing in combination with a variety of different tumor
“-omic” techniques, including those used by Torchia et al. to
identify different prognostic sub-populations based upon a com-
bination of transcriptomics and immunohistochemistry (10).
This approach might enable the identification of patient sub-
populations that harbor potentially actionable mutations that are
associated with a poor prognosis.
We also advocate a systematic genetic comparison of adult and
pediatric AT/RTs in future multinational studies, since loss of
SMARCB1 within a biologically specific developmental window
within neuronal stem cells in utero may be sufficient in itself to
trigger AT/RT formation in babies and infants (4, 11). However,
additional and co-operative non-synonymous mutations in the
post-natal setting may be required for the development of AT/RT
in adults, similar to the paradigm in pediatric ALL where addi-
tional genomic anomalies are required for the pathogenesis of
MLL rearranged B-cell ALL in older children (11).
In this regard, our findings of potentially functionally detri-
mental mutations in a number of genes involved in stem cell
differentiation, such as LNX1 (modulation of NOTCH1 signal-
ing), TIAM2 (regulation of neurite outgrowth), PARD3B (reg-
ulation of cell polarity), and T (an initiator of neuronal stem
cell differentiation) might be hypothesis forming in that pre-
vention of stem cell differentiation, therefore “locking-in” cells
into the stem cell progenitor pool, may be required for effective
SMARCB1-mediated carcinogenesis in post-natal neuronal stem
cells. This would facilitate self-renewal of neuronal stem cells
without any stem cells being able to escape the phenotypic effects
of SMARCB1 inactivation by undergoing differentiation. This
hypothesis awaits confirmation, but we believe that the genetic
findings presented within this paper, in combination with the
exome sequencing data fromWu et al. (7), suggest that the devel-
opment of AT/RT in adults may not be exclusively dependent
upon SMARCB1 inactivation, such that adult AT/RT may not
be markedly dissimilar to other adult brain tumors where co-
operative mutations in a range of genes, reflecting the functional
specialization of different brain regions, may be required for its
pathogenesis.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at http://journal.frontiersin.org/article/10.3389/fonc.2015.00236
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